Gradient Capital Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Gradient Capital Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$239K	Hold	384	–	–	0.06%	160
2026 Q1	$297K	Hold	384	–	–	0.08%	140
2025 Q4	$296K	Sell	384 -1	-0.3%	-$679	0.08%	139
2025 Q3	$216K	Buy	385 +1	+0.3%	+$565	0.06%	158
2025 Q2	$202K	Hold	384	–	–	0.06%	158
2025 Q1	$244K	Hold	384	–	–	0.08%	139
2024 Q4	$274K	Hold	384	–	–	0.09%	129
2024 Q3	$404K	Hold	384	–	–	0.13%	103
2024 Q2	$404K	Hold	384	–	–	0.14%	101
2024 Q1	$370K	Hold	384	–	–	0.14%	111
2023 Q4	$337K	Hold	384	–	–	0.13%	114
2023 Q3	$316K	Hold	384	–	–	0.13%	107
2023 Q2	$276K	Hold	384	–	–	0.11%	125
2023 Q1	$316K	Hold	384	–	–	0.13%	107
2022 Q4	$277K	Hold	384	–	–	0.13%	114
2022 Q3	$265K	Buy	+384	New	+$242K	0.13%	108

Other funds holding REGN

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

WCM

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

AIP

ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return

Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return

HCM

Howland Capital Management Boston, Massachusetts $2.77B AUM 19.56% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

Gradient Capital Advisors's REGN Position: Q2 2026 in Review

Gradient Capital Advisors held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 384 shares worth $239K. The position accounts for 0.06% of the portfolio, ranked #160.

Gradient Capital Advisors first reported a position in REGN in Q3 2022 and has held it in 16 quarters since. The position peaked at $404K in Q3 2024. 229 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Gradient Capital Advisors held 384 shares of Regeneron Pharmaceuticals worth $239K as of Q2 2026.
Gradient Capital Advisors left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
Regeneron Pharmaceuticals made up 0.06% of Gradient Capital Advisors's portfolio in Q2 2026, its #160 holding.
Gradient Capital Advisors first reported a position in Regeneron Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
Gradient Capital Advisors's Regeneron Pharmaceuticals position peaked at $404K in Q3 2024.
229 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Gradient Capital Advisors's 13F filing for Q2 2026, filed 13 Jul 2026.